Tilray Brands, Inc. reported financial results for the second fiscal quarter ended November 30, 2025, with a record net revenue of $218 million in U.S. dollars.
The company saw significant growth in international medical cannabis revenue by 36% and Canadian adult-use cannabis revenue by 6%.
Tilray Pharma achieved record quarterly revenue, positioning the company in a strong financial position with $292 million in cash and marketable securities and approximately $30 million net cash.
Record Net Revenue
Tilray Brands achieved a record net revenue of $218 million in the second fiscal quarter, demonstrating strong performance and market growth.
International Expansion
The company experienced a 36% increase in international medical cannabis revenue, indicating successful penetration into global markets.
Financial Position
With $292 million in cash and marketable securities, Tilray Brands is in a robust financial position, providing flexibility for strategic investments.
- The financial highlights showed a 3% increase in net revenue compared to the prior year period, reaching $217.5 million in the second quarter.
- Gross profit was $57.5 million with a gross margin of 26%, highlighting the company's operational efficiency and revenue generation strategies.
- Cannabis net revenue and gross profit increased, while beverage net revenue experienced a slight decline in the second quarter.
Tilray Brands' strong financial performance and strategic positioning in the cannabis, beverage, and wellness industries reflect its commitment to long-term value creation and sustainable profitability.